Once dismissed as overlooked “cellular debris” buried deep in biological papers, exosomes have now become “liquid gold” in the eyes of capital—an industry valued in the tens of billions.

From obscure laboratory observations to an industrial gold rush, from academic skepticism to commercial frenzy—welcome to the extraordinary voyage of exosomes. Today, let us cut through the hype and decode the “delivery revolution” sweeping across life sciences.

From “Cellular Trash” to an Official Postal System:

The Rise of Exosomes

In 1983, researchers at Johns Hopkins University, while studying sheep reticulocytes, stumbled upon tiny, mysterious vesicles. These particles looked like cellular “trash bags,” filled with proteins the cell no longer needed. The scientific community barely looked up: “Just cellular waste.”

In 1987, Professor Rose Johnstone officially named these vesicles “exosomes”, a term still used today.

A turning point arrived in 1996. G. Raposo and colleagues discovered that exosomes secreted by B lymphocytes carried MHC class II molecules capable of activating T cells in vitro. This was the first evidence that exosomes possess immune-regulatory functions—and it opened the door to their role as “cellular couriers.”

Put simply: a liver cell writes a message, hands it to an exosome courier, which travels through the bloodstream and is received by a kidney cell.

At the time, however, mainstream academia was unconvinced.
“Impossible.”
“Likely contamination.”

Thus, the first era of exosome research quietly ended in doubt. Yet the gears of fate had already begun to turn.

2007: The Moment Everything Changed

In 2007, exosomes staged a dramatic comeback.

A landmark paper published by Jan Lötvall’s team in a Nature family journal revealed that exosomes do not merely carry signals—they transport genetic instructions capable of rewriting cellular fate.

Imagine this: a cell packages its most critical mRNA and regulatory miRNA into an exosome—a biological delivery box—released into bodily fluids. Once received by another cell, these instructions are unpacked, translated into new proteins, or used to reshape gene expression programs.

This discovery was decisive.

Exosomes were no longer passive byproducts—they became the official postal system for genetic communication between cells. Scientific enthusiasm exploded, and laboratories worldwide turned their focus to these nanoscale messengers.

Soon, researchers realized exosomes are everywhere—and always at the center of action:
• In the tumor microenvironment, cancer cells load exosomes with pro-tumor signals and immune-disguising messages, corrupting surrounding healthy tissue and building supply lines for invasion.
• In the world of stem cells, exosomes guide immature cells toward proper differentiation, tissue repair, and regeneration.

Capital Enters the Arena:

The Commercial Frenzy Begins

In 2013, the Nobel Prize in Physiology or Medicine spotlighted the regulation of vesicle trafficking within cells. While the word “exosome” was not explicitly spoken, the message was unmistakable: the cell’s internal logistics system had received the highest scientific endorsement.

Capital listened.

The business logic was suddenly obvious:
If cells naturally manufacture and deploy biological couriers, could humans engineer these couriers into the next generation of precision therapeutics?

Investments poured in.

In 2015, Codiak BioSciences was founded to develop clinical-grade exosome therapeutics for pancreatic cancer. That same year, it raised USD 31 million in Series A financing, followed by USD 61 million in Series B and USD 76.5 million in Series C. In 2020, Codiak successfully listed on NASDAQ.

Meanwhile, exosome-derived biomarkers began to emerge as a cornerstone of liquid biopsy. Compared to circulating tumor cells (CTCs), exosomes are far easier to obtain—present in virtually all bodily fluids. A single blood draw can reveal traces of cancer. According to Precedence Research, in 2022, 7.67% of global IVD companies in the liquid biopsy space focused on exosome and extracellular vesicle detection.

Crossing into Aesthetics and Skincare

Exosomes have also quietly entered the medical aesthetics and skincare arena.

Traditional active ingredients often struggle to penetrate the stratum corneum due to molecular size or stability limitations. Exosomes, however, can deliver miRNAs and proteins by modulating key signaling pathways, achieving efficient cellular fusion and cargo delivery.

Clarins research has shown that keratinocyte-derived exosomes play a critical role in regulating pigmentation. Its product Bright Plus Serum incorporates smooth tiger tail fruit extract to inhibit this pathway at the source.

Sulwhasoo’s Timetreasure Honorstige Cream features ginseng-derived exosomes designed to target multiple aging biomarkers.

As plant-derived exosome technologies continue to advance, more cosmetic brands are entering the field. This “breakout” of plant exosomes is not merely a marketing gimmick—it is the inevitable result of technological maturation, raw material advantages, and evolving market demand.

Beneath the Celebration:

Bubble or Growing Pains?

Behind the excitement, serious challenges loom.

First: purification. How can exosomes be efficiently isolated from massive biological noise?
Second: cargo loading. Precisely loading information into exosomes remains inefficient—akin to manually packing different items into tens of thousands of parcels, a nightmare for scale-up.
Third: regulation. Are exosomes cell therapies? Drug delivery systems? Gene medicines? Regulatory pathways remain unclear, forcing innovators to navigate in the fog.

The harshest wake-up call came from clinical reality.

In 2022, Codiak’s highly anticipated exosome drug failed to meet its primary clinical endpoints. The company’s stock price collapsed overnight. By the following year, Codiak filed for bankruptcy. For the first time, the gap between scientific idealism and clinical reality was laid bare.

At the same time, in the more loosely regulated aesthetics sector, debates erupted. “Stem cell exosomes,” “animal-derived exosomes”—buzzwords multiplied, while oversight lagged behind. Sky-high-priced serums masked opaque ingredient truths. In some cases, the concept of exosomes devolved into little more than modern alchemy wrapped in scientific jargon.

Even within academia, fundamental doubts surfaced:
Could many of the reported “miracle effects” simply be artifacts of cell culture conditions?
When basic scientific consensus begins to shake, the entire field stands at the edge.

The Question That Remains

Today, the exosome industry faces a cold, unavoidable question:

Is this the final illusion before a technological bubble bursts?
Or the painful labor preceding a genuine scientific breakthrough?

The answer lies on a page yet to be written.

⸻

Disclaimer

The information provided in this article is for general reference only and does not constitute professional advice or guarantees.

All companies, organizations, products, and data mentioned (including but not limited to market data and financial figures) are sourced from publicly available information. No warranty is made regarding their accuracy, timeliness, or completeness.

Readers should independently verify and assess the information before taking any action. The author and publisher assume no responsibility for any direct or indirect losses arising from reliance on this content.